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Abstract: Measles virus (MeV), a highly contagious member of the Paramyxoviridae family, causes
measles in humans. The Paramyxoviridae family of negative single-stranded enveloped viruses
includes several important human and animal pathogens, with MeV causing approximately 120,000
deaths annually. MeV and canine distemper virus (CDV)-mediated diseases can be prevented
by vaccination. However, sub-optimal vaccine delivery continues to foster MeV outbreaks.
Post-exposure prophylaxis with antivirals has been proposed as a novel strategy to complement
vaccination programs by filling herd immunity gaps. Recent research has shown that membrane
fusion induced by the morbillivirus glycoproteins is the first critical step for viral entry and
infection, and determines cell pathology and disease outcome. Our molecular understanding of
morbillivirus-associated membrane fusion has greatly progressed towards the feasibility to control
this process by treating the fusion glycoprotein with inhibitory molecules. Current approaches to
develop anti-membrane fusion drugs and our knowledge on drug resistance mechanisms strongly
suggest that combined therapies will be a prerequisite. Thus, discovery of additional anti-fusion
and/or anti-attachment protein small-molecule compounds may eventually translate into realistic
therapeutic options.
Keywords: measles virus; cell entry; fusion protein; structural changes; inhibitors and mechanisms
of adaptation; neuroinvasion; membrane fusion
1. Introduction
Measles virus (MeV) induces measles in humans. MeV is a highly contagious enveloped
virus carrying a negative single-stranded RNA genome and belongs to the Morbillivirus genus
within the Paramyxoviridae family. The Paramyxoviridae family is divided into two subfamilies:
Paramyxovirinae and Pneumovirinae. The Paramyxovirinae subfamily is further divided into seven genera:
Avulavirus, Morbillivirus, Respirovirus, Rubulavirus, Henipavirus, Aquaparamyxovirus and Ferlavirus,
whereas Pneumovirinae is composed of two genera: Pneumovirus and Metapneumovirus [1].
The Paramyxoviridae family includes several important pathogens responsible for high morbidity
and variable mortality among humans and animals. In humans, MeV, mumps virus (MuV), human
parainfluenza virus (hPIV), respiratory syncytial virus (RSV), and human metapneumovirus (hMPV)
cause prevalent diseases, with MeV being responsible for approximately 120,000 deaths annually [2,3].
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Furthermore, henipaviruses (Nipah virus (NiV) and Hendra virus (HeV)) can infect both animals and
humans and are associated with high mortality rates, hence representing a zoonotic threat [4–7].
In veterinary medicine, several members of the Morbillivirus genus are major pathogens. Canine
distemper virus (CDV) causes a widespread disease in domestic carnivores and is responsible
for fatal outbreaks in wildlife [8–13]. Whilst rinderpest virus (RPV) has been eradicated [14],
peste-des-petits-ruminants virus (PPRV) still causes important losses in African and Asian goats and
sheep [15], and in recent years, the aquatic mammal morbilliviruses (Phocine distemper virus (PDV)
and cetacean morbilliviruses (CeMV)) were responsible for dramatic epidemics in wild pinnipeds
and cetaceans [16,17]. Other paramyxoviruses outside of the Morbillivirus genus, such as Newcastle
disease virus (NDV), bovine respiratory syncytial virus (bRSV), and avian metapneumovirus (AMPV)
continue to have a serious impact on animal health and world economics [1].
Both MeV and CDV-mediated diseases can be prevented by vaccination and global MeV
eradication has been considered feasible if 95% herd immunity could be achieved [18]. Although
targeted for eradication, in 2014 MeV was still associated with more than 120,000 deaths
worldwide [19–21]. However, sub-optimal vaccine delivery in developing countries and vaccination
refusal induced by unfounded anxiety concerning the vaccine’s safety in western countries continue
to foster MeV outbreaks. During the last years, the number of MeV outbreaks in USA has been
steadily increasing, and the recent outbreak in Disneyland showcased the importance of sustaining
vaccination campaigns.
Recently, in order to achieve the World Health Organization (WHO)-targeted global MeV
eradication, post-exposure prophylaxis with antivirals has been proposed as a novel strategy aiming
at complementing vaccination programs by filling herd immunity gaps [3]. Indeed, immediate
treatment with antiviral compounds of people exposed to confirmed patients with measles may
contribute to prevent further viral transmission and, thus, prevent an epidemic. This is an attractive
strategy especially because MeV-infected patients present a two-week asymptomatic period before
becoming contagious, thereby offering an excellent window of opportunity for successful prophylactic
interventions. Additionally, and of major importance, blocking MeV outbreaks would likely be
beneficial to combat other infectious diseases. Indeed, Mina and colleagues recently suggested
that long-term MeV-induced immunomodulation enhances the risk of death due to non-measles
infections [22].
Although two inhibitors were recently demonstrated to be efficient in animal models of
morbillivirus-induced disease [23–25], Food and Drug Administration (FDA)-approved anti-MeV
drugs are currently not yet available on the market, thus underlining the need for the development
of additional therapeutic drugs. Moreover, due to a considerable risk of emergence of drug-resistant
viruses, the development of combined therapies with antiviral compounds is indicated.
Paramyxoviruses have two viral glycoproteins, the attachment glycoprotein (HN, H or G) and
the fusion glycoprotein (F). Although F proteins from members of the Pneumovirinae subfamily share
many similarities with those encoded by members of the Paramyxovirinae subfamily, their respective
attachment glycoproteins (Gs) are structurally and likely functionally more distinct [1,26]. For this
reason, this review will mainly focus on and compare the MeV F protein with other paramyxovirinae
F proteins.
2. The Diseases
The pathogenesis of MeV and CDV is very similar. Both viruses enter their hosts through the
respiratory tract and target immune cells residing within the airways [27–31]. After the ensuing
massive amplification in lymphoid organs, which is associated with profound immunosuppression
potentially fostering secondary bacterial infections, both viruses disseminate via the blood stream to
multiple organs leading to gastrointestinal, dermatological and respiratory signs [32].
Viremia may also lead to central nervous system (CNS) invasion whereby MeV and CDV can
induce fatal brain disorders [33,34]. Of note, it has been reported that both viruses, upon CNS
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invasion, likely spread from cell-to-cell in a non-cytolytic manner (without the formation of syncytia);
a phenotype that presumably contributes to the induction of CNS lesions. Indeed, non-cytolytic
cell-to-cell viral transmission represents a mode of lateral dissemination totally different from the
one induced by the same viruses in other tissues where large multinucleated cells are formed
(see Section 3). Although encephalitis of the grey matter is also observed, brain infections with CDV
in dogs usually lead to chronic progressive or relapsing multifocal demyelination, which resembles
multiple sclerosis in humans. MeV can induce primary measles encephalitis, acute post-infectious
measles encephalomyelitis and MeV inclusion body encephalitis (MIBE). It is remarkable that both
viruses can induce a rare diffuse progressive pan-encephalitis, which is known as subacute sclerosing
panencephalitis (SSPE) in humans [35] and old dog encephalitis (ODE) in canines [34]. However, while
brain complications represent a hallmark of CDV infections, they remain very limited in the case of
MeV infections.
3. Cell Entry: The Viral Membrane Fusion Machinery
Viruses are strictly cell-dependent organisms for replication and, therefore, entering a host
cell constitutes a pivotal event in the course of an infection. Armed with the fusion machinery,
morbilliviruses can successfully bypass the first line of defense of the host cell: the plasma
membrane. The morbillivirus fusion machinery is composed of two viral surface proteins forming
hetero-oligomeric complexes. Complexes are composed of tetrameric attachment (H) and trimeric
fusion (F) glycoproteins. It is believed that upon interaction of H with a specific host cell receptor,
a sequential cascade of conformational changes is triggered (first in H and then in F). Ultimately,
these structural rearrangements lead to viral-cell membrane merging, fusion pore formation and
enlargement, and injection of the ribonucleocapsid complex into the host cell cytosol [1]. Importantly,
membrane fusion is not only required for virus-to-cell entry but also for lateral cell-to-cell spread,
which eventually results in multinucleated cell formation (also referred to as syncytia), a hallmark of
morbilliviral and many other paramyxoviral infections.
4. Host Cellular Receptors and Pathogenesis
For viral-cell entry and, presumably, for regular cell-to-cell viral spread (with syncytia formation),
an interaction with the host cellular receptor is mandatory; a task that is specifically carried out
by the viral attachment H glycoprotein of morbilliviruses and the G or HN glycoproteins of other
paramyxoviral genera. While paramyxoviruses carrying an HN attachment glycoprotein (such as
hPIV5, hPIV3 or NDV) detect sialic acid-containing receptors, morbilliviruses and henipaviruses
recognize protein receptors. This and other features (discussed below) suggest relative similarities in
the membrane fusion mechanisms between the morbilliviruses and the henipaviruses as opposed to
other paramyxoviral genera. The attachment protein of henipaviruses (G) binds to the ephrin receptors
ephrin-B2 and ephrin-B3 [36–38], which are largely expressed on vascular endothelial cells and neurons,
largely correlating with viral tropism and pathology [39]. For morbilliviruses, two receptors have been
reported, the CD150 or signaling lymphocyte activation molecule (SLAM) [40,41] and the nectin-4 (N4)
or poliovirus receptor-like protein 4 (PVRL4) [42–45]. The localization of SLAM and N4 on specific
cells nicely correlates with the morbillivirus-induced pathology. Expression of SLAM on activated
immune cells [46] partly explains the observed severe immunosuppression in morbillivirus infections.
On the other hand, N4, which is expressed on the basolateral side of epithelial cells, not only explains
the in vivo epithelio-tropism of MeV and other morbilliviruses, but also why these viruses cannot
directly access the airway epithelia by the respiratory route [43]. Rather, morbilliviruses initially
infect SLAM-positive macrophages and/or dendritic cells residing within the airways [31,47], which
subsequently enable viral amplification throughout the lymphatic tissues. The ensuing viremia then
presumably allows targeting the N4-positive basolateral surface of epithelial cells of many organs,
including the airways [48]. Release of infectious particles from the luminal surface of epithelial cells
in the respiratory tract leads to spread of the infection in the environment through coughing and
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sneezing. Interestingly, CD46, a membrane bound protein expressed in all nucleated cells, was the first
reported functional receptor for MeV [49]. However, it was later demonstrated that CD46 was only
used by MeV vaccine strains; a capacity that very likely emerged from multiple passages of wild-type
viruses in tissue cultures [50]. The usage of human CD46 or a specific orthologue molecule as an entry
receptor for other morbilliviruses remains unclear and deserves further investigation.
In addition to the above described lympho- and epithelio-tropism, MeV and CDV are also
well-known to be neurotropic [35,51], although neurological complications are far more frequent in
distemper than in measles [34]. Remarkably, in the CNS, both viruses were reported to spread from
cell-to-cell seemingly without formation of free viral particles and presumably by microfusions between
infected and target cells, thus spotlighting a unique mode of morbillivirus dissemination [52–56].
Although it has been proposed that an unknown cell surface receptor in neurons might be targeted
by the MeV H protein for entry, subsequent non-cytolytic neuron-to-neuron viral transmission
was postulated to be controlled by the F protein alone [56]. F may directly contact a specific
membrane-bound molecule, which would be sufficient to trigger its refolding and the ensuing
membrane fusion process [57]. The latter postulated microfusion events (also called intercellular
membrane pores) have been recently proposed to be also induced by MeV in well-differentiated
human airway epithelial cells enabling rapid viral spread in the upper respiratory epithelium [58].
In sharp contrast, CDV-mediated non-cytolytic lateral spread in primary cultures of canine
astrocytes was reported to be strictly dependent on the H protein [53]. Moreover, growing evidence
strongly suggests that astrocyte-to-astrocyte nucleocapsid transmission relies on viral functional fusion
machineries that are activated by proper H/receptor contacts [59]. Because both SLAM and N4 were
recently excluded as candidate entry molecules, the putative CDV receptor in astrocytes was arbitrarily
referred to as “GliaR” awaiting precise characterization of this surface molecule [59].
While there are hardly any doubts that the membrane fusion machinery plays an instrumental role
in the initiation of a broad range of morbillivirus-induced pathologies, increasing evidence highlights a
central role of the F protein in fine-tuning the fusion machinery. We propose that variations in degree of
membrane fusion triggering (ranging from microfusion pores to extensive syncytia formation) may lead
to essential differences in ribonucleocapsid transmission dynamics in infected tissues. The latter may
translate into specific primary virally induced pathological changes as well as immunopathological
complications in the frame of the antiviral immune response: two major factors that certainly shape
the clinical course and outcome of an infection.
5. The Fusion Protein F
5.1. General Information
The fusion protein (F) is one of the key components of the morbillivirus fusion machinery.
As for all paramyxoviruses, MeV F is a type I integral transmembrane protein with a cytoplasmic
tail at the C-terminus. Functional F proteins oligomerize as homo-trimers. Each F monomer is first
synthesized as a long inactive precursor (F0) that is processed by furin into two disulfide-linked F1 and
F2 subunits during its transport through the trans-Golgi network (Figure 1A). Furin is a ubiquitous
subtilisin-like cellular endoprotease. Typically, morbillivirus F proteins carry multi-basic residues at
the cleavage site [1,60]. F trimerization likely occurs in the endoplasmic reticulum (ER), the identical
subcellular location where F/H hetero-oligomerization is thought to occur [61], thereby generating
so-called membrane fusion machineries. These hetero-oligomeric complexes are finally exposed at
the cell surface of the infected cells by traveling through the cellular secretory pathway. For MeV,
Brindley and colleagues recently demonstrated that the strength of H/F interaction is strong in the ER
compartment and loosened in the Golgi apparatus, as a consequence of F0 cleavage into the functional
F1/F2 trimer [62]. Thus, in addition to F0 processing, which is a prerequisite for proper F functionality,
the authors proposed that a loosened H/F avidity of interaction (acquired post-F-cleavage) enables
enhanced F’s bioactivity.
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Paramyxovirus F proteins also belong to class I viral fusion proteins [63,64]. This protein type
contains well-conserved regions such as cytoplasmic and transmembrane (TM) domains, two heptad
repeat regions A (HRA) and B (HRB) as well as a new N-terminal hydrophobic segment (generated
upon F0 cleavage), also known as the fusion peptide (FP) [1,65]. MeV F possesses a third heptad repeat
region (HRC) located in the F2 subunit that contributes to the formation of a microdomain around
residue 94, demonstrated to play a role in modulating fusogenicity (Figure 1A) [66]. Importantly, class
I viral fusion proteins are known to initially fold into a structure that contains a high intrinsic energy,
termed prefusion or metastable state. The stability of these prefusion structures is proposed to be
temporally maintained due to a high intrinsic energy barrier. Importantly, it is believed that upon
lowering of the energy barrier, the prefusion state undergoes spontaneous structural rearrangements
until reaching a highly stable final structure, termed postfusion state. The postfusion state of class I
viral fusion proteins exhibits a lower inherent level of energy and displays a well-characterized central
core six-helix bundle (6HB) domain [65,67–69].
It is well recognized that paramyxovirus F’s bioactivity can be modulated by their cytoplasmic
tails (CTs). While long CT domains have been reported to reduce the ability of F trimers to mediate
cell-cell fusion, F complexes carrying short CTs are generally hyperfusogenic [70–72]. For NiV F,
alanine substitutions in a specific motif (KKR) in the CT domain led to the hyper- or hypo-modulation
of the bioactivity through a proposed “inside-out” mechanism [73]. Furthermore, a single tyrosine
residue found in the CT domain of MeV F controls its localization to uropod-like structures in polarized
lymphocytes and to basolateral surfaces of polarized epithelial cells. The latter residue thus influences
the efficiency of viral lateral spread [74], although differences may exist depending on the viral strain
studied [75].
Several works additionally reported that the TM of paramyxovirus F proteins could also modulate
membrane fusion activity of F complexes, therefore highlighting a role of the TM segment beyond a
simple anchor in the lipid bilayer [76]. In the case of MeV F, substitutions performed within the TM
region were proposed to influence bioactivity by altering the availability of active membrane fusion
machineries at the cell surface [77].
5.2. F Structural Information
No structural information is yet available for any morbillivirus F proteins. However, atomic
structures of soluble F protein ectodomains in their pre and/or postfusion conformations were recently
solved for several paramyxoviruses [78–86]. In the case of hPIV5 F, the recently determined crystal
structure of the prefusion state highlighted a “tree”-like fold [85,86]. A short stalk region, mainly
composed of the three HRB regions assembling in a three-helix bundle (3HB) structure, was found
supporting a large globular head domain. The globular head domain has been divided into the three
previously identified subdomains per subunit; DI, DII and DIII [80,86]. While DI and DII are forming
the base of the head, DIII is mainly constituted of HRA segments that locate at the top of the head
structure. In the prefusion state, HRA is composed of eleven segments (four helices, two ß-strands and
five loops). Comparison of the pre (hPIV5 F) and postfusion (hPIV3 F) states showed that DI and DII
remained mostly unaltered, whereas the eleven HRA segments of DIII were drastically different in
both structures (Figure 1B,C). It is also noteworthy that the FP is found mostly buried in the prefusion
structure. Indeed, the DII and DIII domains of two different monomers appear to be “clamping” the
FP within the globular head domain [86]. The FP is not visible in the postfusion state, but due to the
conformation of the 6HB fold, it is believed that both the FP and TM domains may be engaged in
physical interactions.
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Figure 1. Structure/function of the easles virus ( e ) fusion protein. ( ) The i portant functional
do ains of F are color-coded. The F1 and F2 subunits are sho n. hile the I (light blue), II (dark
blue) and III (green) do ai s efi e t e glo lar ea o ai , t e re io efi es t e stal .
T : transmembrane domain; CT: cytoplasmic tail; HRA-C: heptad repeat region A–C; FP: fusion
peptide; HBD: H-binding domain; SPase: signal p ptidase. (B and C) Structural differences b tween
th pre and postfusion state f F. Images were obtained from homology models performed with the
canine distemper virus (CDV) F sequence (strain A75/17) and based on the atomic coordinat s of the
human parainfluenza virus type 5 (hPIV5) F prefusion state (PDB 2B9B) and hPIV3 F postfusion state
(PDB 1ZTM). DI, DII and DIII are color-code as indicated in (A). Im ges were generated using either
th PyMol (high r solution) or Sculptor (low resoluti n) softwa e packages (D) Model of membr ne
fusion induced by easl s virus F. Once activated by H, prefusion F may dis ngage from H interaction.
Then the HRB region of the stalk may m lt, which c sequently may enabl he 11 segments positioned
in the globular head to rearrange into a lon three-helix bundle (3HB) coiled-c il. T is would in turn
propel the fusion pept de at the top of the 3HB and allow its insertion into the target plasma membrane.
This prehairpin interm diate then collapses, w ch brings both me branes into l se roximity. Finally,
F may r ach th highly stable postfusion state, which c rries the six-helix bundle (6HB) formed by
HRA and HRB s gments. This stage is thought to correlate with membrane merging and ensuing
fusion pore opening. This odel likely req ires the conce ted action of more than one F molecules.
This model has been described first by Yin and colleagues [79,86].
Additionally, a very recent crystal structure of NiV F was reported to consist of hexamer-of-trimers.
This higher oligomeric F structure was also observed via biochemical assays and in F-containing
viral-like particles (VLPs) by cryo-electron microscopy. Mutations at the trimer-trimer interfaces
of the hexamer modulated the fusogenicity of F in both cell-cell fusion and pseudotyped virus
entry assays [82]. This hexamer-of-trimer F arrangement could have impactful repercussions in
our understanding of triggering of F by the attachment protein, and in fusion pore formation and
expansion during the membrane fusion process.
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5.3. The F-Refolding Cascade
Upon H-mediated triggering, metastable, prefusion F trimers undergo a series of spontaneous and
irreversible conformational changes. The cascade of F structural rearrangements is proposed to follow
a sequence of several steps: (i) the stalk domain (formed by three compact HRB domains) is thought to
open up; (ii) the eleven segments of the HRA region of the three monomers then refold into an extended
coiled-coil conformation, thereby allowing the relocation and insertion of the terminal FP into the target
membrane, generating the so called “prehairpin” intermediate (PHI) and (iii) the three HRB peptides
swing around the base of the globular head to dock onto the coiled-coil, thus generating the final 6HB
core structure, typical of the postfusion state (Figure 1D) [1,86,87]. This cascade of refolding steps is
believed to be associated with membrane fusion because full 6HB assembly infers that, as mentioned
above, the TM domain (embedded in the viral envelope) and the fusion peptide (anchored in the
host cell membrane) are brought into immediate proximity, in turn inducing membrane curvature,
outer lipid monolayers’ disturbance and ensuing spontaneous membrane merger [88–90]. Importantly,
the energy released when F refolds from the metastable prefusion state to the thermodynamically
highly stable postfusion conformation is thought to overcome the free energy of the lipidic fusion
intermediate structure, allowing the creation of the fusion pore.
Interestingly, full completion of the 6HB structure for triggering the paramyxovirus entry process
has been recently challenged. Indeed, membrane fusion activity was triggered by MeV F variants
displaying two covalently bound HRB domains, thus physically precluding complete 6HB assembly.
These data therefore suggested that full completion (and/or proper assembly) of the 6HB structure
was not necessarily required for membrane fusion induction and ensuing fusion pore opening [91].
This provides critical information for the design of antiviral drugs with desirable efficacy profiles.
6. The F-Activation Stimulus
6.1. The Receptor-Binding H Protein: General Information
In contrast to other important infectious pathogens, such as human immunodeficiency virus
(HIV), influenza or Ebola virus, most members of the Paramyxoviridae family rely on a cofactor for
proper activation of the fusion protein: the attachment protein [1]. Therefore, to gain a fundamental
knowledge on the cell entry process of these enveloped RNA viruses, it is of critical importance to
precisely understand the molecular dynamics employed by the attachment protein to translate receptor
binding into F activation.
The attachment proteins of paramyxoviruses evolved in different ways, reflecting their
biological adaptation to specific host-receptors. Therefore, for avulaviruses, rubulaviruses and
respiroviruses, the attachment protein binds to sialic acid-containing receptors for cell entry [92,93].
These proteins also contain an enzymatic neuraminidase activity that cleaves sialic acid from
the progeny virus particles and therefore facilitates the budding event by preventing viral
self-agglutination and/or prolonged binding to the host cell. Additionally, these attachment
proteins carry the typical hemagglutination activity. For these reasons, such receptor-binding
glycoproteins were referred to as hemagglutinin-neuraminidase (HN) proteins. For pneumoviruses,
metapneumoviruses and henipaviruses, the attachment protein neither possesses the hemagglutination
nor the neuraminidase activities. Thus these attachment proteins have been designated as glycoprotein
(G). For morbilliviruses, the attachment protein maintained the hemagglutination function but lost the
neuraminidase activity. Such receptor-binding proteins were therefore referred to as hemagglutinin
(H) proteins [1].
The attachment proteins of paramyxoviruses are type II integral transmembrane proteins. Hence,
each glycoprotein contains a short cytosolic N-terminal cytoplasmic tail and a large extracellular
C-terminal domain, connected via a single-spanning hydrophobic TM domain. The extracellular region
(or ectodomain) is further divided into a membrane-proximal stalk region and a large membrane-distal
cuboidal or globular head domain, presumably linked by a flexible connector.
Viruses 2016, 8, 112 8 of 30
Upon translation of MeV H monomers in the ER, four units physically associate to form tetrameric
structures composed of a “dimer-of-dimers.” Each dimer is built-up by two monomers that are
covalently bound via two disulfide bonds located in the upper part of the stalks (Cys-139 and
Cys-154) [94]. In contrast to covalent dimers, the dimer-of-dimers interface likely relies on hydrophobic
interactions. H oligomerization, glycosylation and assembly with F trimers all occur in the ER
compartment and, as stated above, membrane fusion machineries are subsequently exposed on the
host cell plasma membrane following the cellular secretory pathway.
6.2. Structural Information
6.2.1. H-Heads
Structural studies of several paramyxovirus monomeric H heads (with or without ligands)
revealed a common tertiary folding, characterized by a six-bladed beta-propeller conformation [95–107].
The beta-propeller head contains distinct functional receptor binding sites. For G and HN attachment
proteins, the receptor binds to a deep cavity located at the top of the propeller structure [95,98].
Conversely, the MeV H head, despite equally featuring the deep pocket at the top of the barrel,
interacts with multiple receptors much more sideways [103,104].
6.2.2. H-Stalks
The only structural information available for any paramyxovirus’ attachment protein stalk
domains is derived from hPIV5 and NDV. The atomic structure revealed four α-helices that tetramerize
to form a four-helix bundle (4HB). While the upper part of the 4HB folds into a quite straight
conformational state (with an 11-mer repeat), the lower part displays a supplementary left-handed
supercoiled configuration (with a 7-mer repeat) [105,107]. Importantly, we and other groups have then
provided strong evidence that a 4HB-like conformation is the most likely structure also assumed by
the morbillivirus H-stalk domain prior to receptor binding [108–110].
6.2.3. Tetrameric Attachment Protein Structures
MeV H
Hashiguchi and colleagues determined in 2011 the crystal structure of MeV H-heads in complex
with the immune cell SLAM receptor [103]. Furthermore, beyond revealing the precise binding
interface, they obtained crystals of MeV H assuming two different tetrameric configurations. In more
detail, these atomic structures first revealed that the position of the two monomeric heads forming the
dimers was very similar. In contrast, the dimers were assembling differently towards each other in the
two tetrameric configurations. Indeed, while in configuration I, the dimers were assembling in a quite
planar manner (Figure 2A), in configuration II, they were assembling in a much more staggered way
(Figure 2B). This inferred for the first time the notion that the dimers may represent structurally “rigid”
units that can “move” as two independent blocks to adopt discrete configurations.
NDV HN
The latest structural information of the soluble NDV HN ectodomain was totally unexpected.
Not only part of the stalk domain was visible in the crystal for the first time, but the structure
additionally illuminated an intriguing positioning of the two dimeric head units. Indeed, while
both dimeric heads were not engaged in any tetrameric interface, they were, rather, backfolding onto
the stalk with the lower head of each dimer, making a short-range interaction with the upper part of
the stalk domain. The latter structure was referred to as the “four-heads-down” conformational state
(Figure 2C) [105].
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morphed into low‐resolution images using the Sculptor software package; (C and D) Two alternative 
folds  of H  tetramers.  Images were  obtained  from  homology models  performed with  the  canine 
distemper virus CDV) H sequence (strain A75/17) and based on the atomic coordinates of Newcastle 
disease virus (NDV) HN (PDB 3T1E) and hPIV5 HN (PDB 4JF7). The dimers of the attachment protein 
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Figure 2. Possible structure(s) of the MeV attachment protein. (A and B) Crystal structures of
MeV H in complex with the receptor signaling lymphocyte activation molecule (SLAM) (not shown).
Two tetrameric configurations were determined (PDB 3ALZ and 3ALX). High-resolution structures
were morphed into low-resolution images using the Sculptor software package; (C and D)
Two alternative folds of H tetramers. Images were obtained from homology models performed with
the canine distemper virus CDV) H sequence (strain A75/17) and based on the atomic coordinates
of Newcastle disease virus (NDV) HN (PDB 3T1E) and hPIV5 HN (PDB 4JF7). The dimers of the
attachment protein tetramer are color-coded in green and red.
hPIV5 HN
The most recent X-ray structure of a soluble form of the hPIV5 HN attachment protein ectodomain
featured an intriguing “hybrid” conformational state. In this conformation, only one dimeric unit
was backfolding onto the stalk, whereas the other one was positioned in an “up” state due to a helix
extending beyond the 4HB-stalk structure. This HN conformation indicated a tetrameric interface
between one head of the dimer in the “up” state and one head of the next dimer assuming the “down”
state. This HN structure was referred to as the “two-heads-up and two-heads-down” conformation
(Figure 2D) [107].
6.3. Functional Information
Pioneering work done in the field has demonstrated that membrane fusion activity induced
by members of the Paramyxovirinae subfamily requires the concerted action of the F and attachment
glycoproteins [111–113]. While the head domains of the paramyxovirinae attachment glycoproteins
were reported to contact host cell surface receptors, compelling functional and biochemical evidence
supports the idea that the stalk region of the attachment proteins is the domain predominantly involved
in short range interaction with F trimers [1,114–119].
Importantly, beyond supporting F-interactions, recent studies reported strong evidence in support
of the H-stalk also carrying the F-triggering activity. Strikingly, through consecutive substitution
of residues within the stalk domain of CDV and MeV H proteins into cysteines, supplementary
disulfide bonds trapping H tetramers could be successfully generated [108–110]. Remarkably, when
engineered covalent bonds were located within the central region of the H-stalk, bioactivity was
blocked and, most importantly, restored when H/F-expressing cells were treated with mild-reducing
conditions. These results provided the first functional evidence suggesting that H-heads’ engagement
with its cognate receptor triggers structural rearrangements within the central stalk section, which are
strictly required for F-activation. Moreover, microdomains within both MeV and CDV H-stalks were
mapped: while the F-binding domain (FBD) may consist of residues 110–118, F-triggering may be
supported by the broader 85–118 overlapping section [108,114,120,121]. Furthermore, and remarkably,
attachment protein constructs lacking the head domains remained, at least partly, functional for most
paramyxoviruses (hPIV5, MeV, NDV, MuV, NiV and CDV), thereby clearly spotlighting the critical
F-triggering role of the HN, G, and H-stalk domains [122–126].
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Additionally, a recent functional analysis of the 167–188 segment of MeV H revealed that this
microdomain could accommodate mutations without altering H’s fusion-promotion ability, whereas
conversely, insertions or deletions within this segment drastically affected the bioactivity of H-mutants.
Combined with the fact that this H-segment remained invariably unresolved in all available MeV
H-head crystal structures, the above mentioned functional and biochemical analyses suggest structural
flexibility of the 167–188 H-microdomain [127]. Evidently, a flexible linker connecting the stalk to
the head domain may offer sufficient structural freedom to enable the proposed receptor-induced
repositioning of both H units (head and stalk) that may translate into F activation (see below).
7. The Putative F-H Binding Interface
It is well accepted that the paramyxovirus attachment protein is engaged in short-range interaction
with the fusion protein. However, no structural data of F in complex with the attachment protein is
currently available, thus precluding a comprehensive molecular understanding of the HN/H/G-F
mode of interactions. Importantly, the timing of assembly between the attachment and fusion proteins
seems to vary considerably among different members of the Paramyxovirinae subfamily. For instance,
hPIV5 HN may engage with F only at the cell surface, and likely only after HN receptor binding,
whereas the morbilliviruses H and F glycoproteins are thought to associate already intracellularly
prior to receptor binding [128]. Additionally, henipavirus G and F associate at the cell surface prior to
receptor binding [73,129,130], but whether or not they associate intracellularly is still unclear.
Nevertheless, several functional studies recently highlighted candidate residues in the F heads and
attachment protein stalks that may putatively contribute to reciprocal physical interactions. For MeV
and hPIV5 F proteins, few hydrophobic amino acids located at the base of the F trimer globular
head and near a hydrophobic pocket (formed by two adjacent protomers) were recently identified as
candidate H-contacting residues [131,132]. More precisely, these hydrophobic residues were located
in a region assuming an immunoglobulin (Ig)-like fold mapping within the DII domain of the F
globular head structure (Figure 3A; H-binding domain; HBD). However, while for MeV the strength
of the H/F interaction was only partially reduced by substituting these critical residues individually,
biochemical evidence (co-immunoprecipitation (co-IP)) could not be provided in the case of hPIV5 F
and HN interactions. In a third report, two candidate hydrophobic residues in the CDV F globular
head (also located in the Ig-like domain) were demonstrated to also potentially contact CDV H. Once
substituted in a combined manner into charged residues, the resulting F-variants exhibited strong
impairments in physical association with H (assessed by co-IP), while preserving the prefusion state
and substantial cell surface expression profiles [133].
On the other hand, as mentioned above, the H-stalk region 110–118 was identified as a putative
candidate region involved in short-range interaction with F (FBD) [114,134]. These findings taken
together suggest a staggered model of H/F hetero-oligomeric assembly, where the Ig-like microdomain
of the F globular head domain contacts the H-stalk central region (Figure 3B). While this model of H/F
assembly infers that the receptor-binding H head modules may be positioned above F trimers, further
functional and structural studies are warranted to validate or refute this idea. Supporting this notion,
recent evidence suggest that H glycoprotein spikes are “taller” than F glycoprotein spikes, and that
this relative height difference is important for the membrane fusion triggering process [134].
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8. Energetics of F Activation
Concerning the energetics required for F activation mediated by paramyxovirus attachment
proteins, the “clamp” and “provocateur” models have been suggested [128,135]. The “clamp” model
emerged from the fact that some paramyxovirus fusion and attachment proteins form hetero-oligomer
complexes already intracellularly and travel together to the cell surface (as for MeV) [61]. Therefore,
it has been hypothesized that, in this case, attachment proteins act as a molecular scaffold that is
necessary to maintain F trimers in the metastable, prefusion state, thereby preventing premature
activation. This indirectly suggested that such paramyxovirus F trimers would contain low energy
barriers in turn precluding proper stabilization of the metastable state in the absence of H. Hence,
upon binding of these attachment proteins to a specific host cellular receptor, F would be released from
the “clamp”. In turn, F complexes would be destabilized and consequently spontaneously undergo
the irreversible refolding cascade.
The “provocateur” model is based on the fact that some paramyxovirus attachment and
fusion proteins do not associate intracellularly (as for hPIV5) [136]. Thus, the formation of
hetero-oligomeric complexes may occur only as a consequence of attachment proteins binding to
a receptor. A conformational modification of the attachment proteins is then required to actively
destabilize F trimers. Therefore, the “provocateur” model infers that the prefusion F state of such
paramyxoviruses can be maintained alone, thereby relying on a signal from the attachment protein that
actively lowers the energy barrier for the initiation of the ensuing spontaneous refolding cascade [135].
Remarkably, taking advantages of conformation-sensitive monoclonal antibodies, the most recent
data in the field, however, demonstrated that the morbillivirus and henipavirus F proteins are stable
enough to maintain the prefusion state in the absence of H or G [110,137,138]. These findings hence
argued against the “clamp” model, while conversely supporting a version of the “provocateur” model
for morbilliviruses and henipaviruses. Since H/F and G/F associations are clearly detected before
receptor binding, this, in turn, points to some version of the “provocateur” mechanism as a common
theme potentially used by all Paramyxovirinae to productively trigger F complexes for refolding.
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Overall, these data taken together clearly infer that morbillivirus H tetramers (and probably most of
the Paramyxovirinae attachment proteins) must structurally rearrange upon receptor contact to actively
trigger F for membrane fusion, even when attachment/F complexes are already previously interacting.
9. Latest Models of F Activation
While, as described above, a quite precise mechanistic knowledge on the F refolding cascade to
achieve membrane fusion starts to emerge from a panel of mechanistic and structural studies, how
H translates receptor binding to F triggering remains largely unknown. However, it is now well
accepted that the H protein very likely undergoes some conformational changes as a consequence of
receptor engagement, which ultimately lead to F activation. Five main models currently propose how
H tetramers may “move” to actively trigger F trimers.
9.1. The Sliding Model
As mentioned above, the structural data obtained with MeV H illuminated two different tetrameric
configurations [103]. Based on these two structures, the authors proposed one model of H-mediated F
activation. In this model, H would first fold with the H-heads assuming conformation I (with both
dimers associating in a relatively planar configuration) and the stalks adopting the compact “closed”
4HB conformational state. Upon H-heads receptor binding, the H-heads would “slide” laterally to
finally achieve conformation II (with dimeric heads assembling in a relatively staggered configuration).
As a result, H-stalks would (partially) dissociate and, in turn, lead to the disengagement of F from
H. Subsequently, F complexes would be free to undergo the required structural rearrangements to
mediate membrane fusion (Figure 4A).
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Figure 4. Models of F activation by paramyxovirus attachment proteins. (A–E) Latest models have
proposed how attachment protein of different members of the Paramyxovirinae subfamily activates F as a
consequence of attachment protein-receptor binding. Importantly, all models predict a receptor-induced
overall re-positioni g of the head regions upon receptor engagements, whi h may then act as a
universal co e echanism for F activation (firs escribed by Bose and colleagues [122]). H tetramers
are colored in green. Pre-activated F and activated F are highlighted in blue and red, respectively.
In model (D) (bi-dentate model) the conformational changes occurring within the head domain prior
to heads’ re-positioning are represented by oval structures. The attachment protein stalk regions that
are implicated in F activation are shown as black lines (models B–D).
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This mechanism infers that MeV H-heads, upon receptor binding, may generate specific signals
that would travel through the flexible linkers down to the stalks for efficient F activation. However,
latest mechanistic data obtained are not in direct agreement with the sliding model. First of all,
head/stalk hybrid attachment proteins were reported to preserve F-triggering activity, provided that
the stalks and the F protein originated from the identical virus [139]. Considering that the entire
head/receptor framework is swapped in such chimeric attachment proteins, it is difficult to believe
that specific receptor-induced conformational changes could be maintained. Secondly, and most
importantly, it was recently documented that, for most paramyxoviruses (hPIV5, MeV, NDV, MuV,
NiV and CDV), engineered “headless” attachment protein constructs remained bioactive, although
to limited extend for some specific constructs [122–126]. We note that fusion promotion by headless
attachment proteins was equally induced regardless of the presence or absence of the receptor. These
data suggest that the head modules are not necessary to send specific “signals” down to the stalk
for productive F activation. However, it is possible that specific signals are sent from the head to the
stalk, but that removing the head gets rid of the need for transport of such specific signals. Thirdly,
a recent report demonstrated that SLAM-variants displaying mutations in the binding site defined
by the interaction of CDV H assuming the putative configuration II, did not substantially modulate
H/F-induced membrane fusion activity [140]. Consequently, the biological relevance of the two MeV
H-tetrameric conformations for the membrane fusion process deserves future investigations.
9.2. The Stalk-Exposure/Induced Fit Model
The second model is based on latest structural and mechanistic information obtained for NDV
and hPIV5 HN-proteins. Here, the authors proposed that the “four-heads-down” conformation may
represent the initial, pre-receptor-bound, structural state adopted by HN. As described above, this
state is characterized by two heads (the lower ones of each dimeric head unit) making physical
contacts with the C-terminal region of the HN-stalks and, consequently, directly covering the putative
F-binding/activation site [105]. Therefore, such a native conformational state would evidently prevent
intracellular HN/F interaction. Upon HN-heads receptor engagement at the cell surface, the dimeric
head units would move in an “up” state, which, at the same time, uncover the F-binding/activation site.
F would be now free to contact HN-stalks and be activated through a putative induced fit mechanism
(Figure 4B) [123,128]. Therefore, this model nicely integrates the surprising data spotlighting the
receptor-independent constitutive bioactivity mediated by headless attachment protein constructs:
prior to HN-receptor binding, two head modules would inhibit assembly of HN/F complexes, thus
preventing premature F activation and ensuing membrane fusion induction. Conversely, in absence of
HN-heads, premature glycoproteins’ assembly may occur and induce untimely F activation, thereby
eventually promoting membrane fusion in a dysregulated and receptor-independent manner (with F
being randomly triggered at the cell surface).
Although the “stalk-exposure/induced fit” model for F activation may present features common
to all members of the Paramyxovirinae subfamily, a large body of evidence suggest that MeV, CDV,
hPIV3 and NiV membrane fusion machineries can already form intracellularly [61,129,141,142].
Additionally, stalk-elongated, and presumably head-lifted, MeV and CDV H constructs remained fully
bioactive [126,134] and specific H-stalk mutants exhibit loss of F interactions both in receptor positive
and negative cells [108,134], which clearly indicates that some variations of the model may exist.
9.3. The Safety-Catch Model
Based on the most recent mechanistic data, it was hypothesized that CDV and MeV H tetramers
may initially fold into an auto-repressed conformation, where the H-heads (perhaps by adopting a
conformational state resembling the “four-heads-down” HN state) may temporarily lock the inherent
F-triggering bioactivity of the stalks by presumptive head-to-spacer stabilizing interactions [62,124,126].
Of note, the morbillivirus H-stalk displays a supplementary segment in the stalk domain (termed
“spacer” [109]; Figure 3B), located between the F-binding/activation microdomains and the putative
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flexible connectors and ensuing cuboidal head modules. This supplementary H-stalk domain may
consequently lead to higher positioning of the head domains with respect to the putative F-binding site
and thus eventually reducing the probabilities of heads-mediated putative steric hindrances preventing
intracellular F-binding. The “safety-catch” model therefore suggests that F complexes can interact with
H tetramers without premature activation because H initially assumes an auto-silenced conformation.
De-activation of the H auto-repressed state is achieved as a consequence of H-heads’ receptor-binding,
in turn leading to re-positioning of the head modules away from the stalks. This results in the
disruption of the key stabilizing head-to-spacer interactions, thereby offering freedom to the stalks
that will consequently spontaneously undergo structural rearrangements within the central section
(also encompassing the F-binding site), which translate into F-triggering (Figure 4C) [62,124,126].
9.4. The Bi-Dentate Attachment Protein/F Interaction Model
Liu and colleagues recently introduced another variation of the F-triggering mechanism induced
by the attachment protein of NiV [125]. Although the authors identified a receptor-induced
“stalk-exposure”-like conformational change in NiV G, both glycoproteins were previously reported to
assemble already intracellularly, as in the case of MeV and CDV membrane fusion machineries. Here,
a “bi-dentate” attachment protein/F interaction mechanism was hypothesized to exclude premature
F activation upon early G/F interaction. This model predicts that, initially, NiV F may bind to the
attachment protein head domains. NiV G engagement to its cognate receptor would then trigger
conformational changes in G (including two occurring in the G head domain and followed by a
“stalk-exposure”-like movement) that enables F to switch, or relatively gain, interactions from the
heads to the stalks, in turn resulting in F activation (Figure 4D) [125]. Noteworthy, this model is not
mutually exclusive with the “safety-catch” model, which could also explain the current NiV data.
Although possible for NiV F activation, recent data obtained for CDV and MeV H proteins are not
in agreement with this hypothesis. As already mentioned above, H tetramers with elongated stalks
remained bioactive and H-stalk variants lost binding competence to proteolytically matured F trimers,
even in receptor-negative cells [62,108,134]. Moreover, “headless” H constructs retained intracellular
F interaction [62]. Whether NiV F is activated by G through the proposed “bi-dentate” mechanism
or via a mechanism more closely resembling the one hypothesized for morbilliviruses (“safety-catch”
model) remains to be determined.
9.5. The Receptor-Induced Oligomerization Model
Recent EM observations of hPIV3 HN/F complexes anchored on virions’ envelopes suggested that
both glycoproteins may associate already prior to receptor engagement. Additionally, a sub-population
of HN-proteins, in complex with F, were displaying “heads-up”-like configurations, in turn inferring
that the HN “heads-up” conformation is not sufficient to activate F [143].
Using bimolecular fluorescence complementation technology, Porotto et al., additionally obtained
a series of data suggesting clustering of preformed HN/F complexes upon receptor engagement [144].
Taken together, these data led the authors to propose an alternative model whereby HN may transmit
a signal for F activation that is triggered by a receptor-induced H-oligomerization mechanism
(Figure 4E) [143]. However, although a similar mechanism was proposed for hPIV5 years ago [145–147],
this model currently lacks experimental evidence confirming that monomeric, dimeric or tetrameric
HN-structures can switch to higher order oligomers as a result of interaction with the receptor to
ultimately achieve conformations productive for F activation.
Taking together, it becomes increasingly evident that, to gain further key information of the
membrane fusion process, acquisition of novel structural information is mandatory. More specifically,
the determination of any paramyxovirus attachment protein in complex with F at atomic, or
near-atomic, resolution would certainly highlight instrumental insights of the molecular mechanism
sustaining paramyxovirus cell entry. Of note, high-resolution structural information can be now
gathered using cryo-transmission electron microscopy (TEM) and single particle 3D reconstruction
Viruses 2016, 8, 112 15 of 30
from electron micrographs recorded with the revolutionary direct electron device (DED) technology.
This may set an innovative framework not only to obtain structural information of HN/H/G-F
complexes to unprecedented levels, but also to deliver critical information for antiviral drug design.
10. The Concept of the F-Triggering Range
Recently, we and others have proposed that the capacity of lowering the intrinsic energy barrier
of the prefusion F state varies depending on the particular triggering stimulus [148,149]. Such stimulus
relies on the molecular nature of H and the origin of the cellular receptor. The combination of the
triggering stimulus with the intrinsic F protein metastability then defines the so-called “F-triggering
range”, or the capacity of a given F to be activated to mediate membrane fusion in a given cellular
environment. In other words, we predict that the specific contacts between H tetramers and a host cell
receptor open a range of F-triggering possibilities. If the F protein contains an inherent energy fitting
within this range, then H can lower the energy barrier of such F complexes to levels sufficient for their
destabilization and activation [148].
Therefore, we propose that the H/SLAM interaction leads to the opening of a wide F-triggering
range, thus enabling even highly stable F complexes to be destabilized for membrane fusion. On the
other hand, the H/N4 association results in a narrower F-triggering range. Thus, in such environmental
conditions, highly stable F complexes would not be activated at all or only to levels displaying only
limited cell-cell fusion efficiency [148]. As a matter of fact, for a given virus, massive syncytia
formation is observed in Vero-SLAM cells compared to those formed in Vero-N4 cells (when very
similar amounts of receptors are expressed at the cell surface), an in vitro situation that seems to
correlate with in vivo observations.
The A75/17-CDV strain is highly neurovirulent: it can induce demyelinating encephalitis
associated with persistent infection of astrocytes [150–152]. As mentioned above, we obtained evidence
that an unknown molecule may act as a functional receptor for CDV in astrocytes (referred to as GliaR)
allowing cell entry and spread [59]. Therefore, we hypothesize that the H/GliaR mode of interaction
provides a suboptimal F-triggering range. The latter combined with the exceptionally high intrinsic
stability of A75/17-F will translate into poor membrane fusion triggering presumably restricting
cell-cell fusion to microfusion pores and, in turn, allowing swift transfer of ribonucleocapsids between
cells. This mechanism may eventually explain how CDV “outruns” the immune system and leads to
viral persistence associated with a unique pattern of progressive multifocal white matter destruction.
11. Development of MeV F Inhibitors
Because MeV-mediated clinical symptoms are, at least in part, immunopathological in nature and
occur at a time when viral clearance is already advanced, the usage of antivirals to cure full blown
measles is probably unproductive. Nevertheless, it was recently proposed that MeV antiviral drugs
may potentially synergize with current vaccination programs to achieve the threshold of 95% herd
immunity that is required for successful global MeV eradication. Hence, post-exposure prophylaxis of
people exposed to confirmed cases of measles may potentially help to contain epidemics [3].
Importantly, although neurological complications of MeV infection such as SSPE and MIBE are
rare, they often remain unrecognized in developing countries because these complications occur
months to years after the acute infection [35]. However, since SSPE and MIBE are crippling and
lethal diseases, the potential effectiveness of inhibitors in patients with confirmed MeV-induced
neurological complications should be investigated. We note that two promising candidate inhibitors
were recently proven to protect against virulent morbillivirus challenge in established animal models:
a small-molecule anti-polymerase inhibitor and a peptidic entry inhibitor [23–25]. This underscores
the need for the development of new inhibitory molecules, which would be of utmost importance
for combined antiviral therapeutic strategies to prevent the rapid emergence of drug-resistant
viral variants.
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11.1. Anti-F Peptidic Inhibitors
As mentioned above, the MeV F protein, like all class I viral fusion proteins, contains two
conserved heptad repeat (HRA and HRB) regions. While HRA locates near the N-terminal region of
the proteolytically mature form of the membrane-anchored F1 subunit, HRB is found proximal to the
C-terminal TM domain of the identical subunit. As first noted for the HIV gp41 glycoprotein [153,154],
peptides derived from either heptad repeat have been shown to act as potent inhibitors of the fusion
process [153,155–160]. It is widely accepted that HRB-derived peptides target a structural intermediate
(presumably the HRA-derived extended coiled-coil of pre-hairpin F) that transiently emerges during
the refolding cascade, thereby interfering with formation of the 6HB-carrying central core of the final
postfusion state.
As first demonstrated for HIV, NiV, and hPIV3, increased inhibitory efficacy was obtained by
conjugating a cholesterol group to the peptides [161–163]. Such modified peptides could efficiently
prevent lethal challenge with NiV in mice [161]. Importantly, similarly conjugated MeV F HRB-derived
peptides were recently documented to also potently inhibit viral spread in brain explants as well
as in an animal model recapitulating MeV encephalitis [25]. Based on the latter modifications, the
anti-F peptidic entry inhibitor was demonstrated to (i) exhibit longer half-lives; (ii) display high
efficacy after simultaneous subcutaneous and intranasal administration; and (iii) efficiently cross
the blood-brain-barrier (BBB), indicating a possible therapy for MIBE and SSPE. Assuming that
viral transmission in the brain would indeed rely on functional F proteins completing a bona fide
refolding process to induce membrane fusion for transmitting the ribonucleocapsid from one cell to
another, anti-F peptidic inhibitors could potentially abrogate this process in patients with MeV-induced
neurological diseases.
11.2. Anti-F Inhibitory Antibodies
Several highly efficient neutralizing monoclonal antibodies (nAbs) targeting MeV F-trimers were
produced decades ago [164,165]. Importantly, while passive immunization (with immunoglobulins)
within seven days of exposure may prevent measles [166], treatment with specific anti-F nAbs
were not only neutralizing but able to passively protect mice [164]. Interestingly, it has been
only recently reported that some of the generated anti-F nAbs were specifically recognizing the
prefusion F conformational state [137]. Although the molecular mechanism of neutralization remains
undetermined, it is conceivable that the nAbs either over-stabilize prefusion F and/or physically
restrict the initiation of the large structural rearrangements. Alternatively, they may also lead to
untimely H/F dissociation. Of note, not all prefusion F-recognizing mAbs are neutralizing. Indeed,
a prefusion CDV F-specific monoclonal antibody could neither inhibit viral cell entry nor cell-to-cell
spread [137]. This underscores the intriguing concept that some epitopes within the metastable state of
F trimers can accommodate binding of one (or more) monoclonal antibody with little to no impact on
the series of irreversible large-scale conformational changes that lead to membrane fusion.
Independently of the mechanism of inhibition, considering that infants and young children
are the primary target of anti-measles therapy, monoclonal antibodies may not exhibit a suitable
pharmacological profile. First, as mentioned above, immunopathological reactions in fulminant
MeV infections will not respond to, or even be aggravated by, this treatment. Second, if used for
post-exposure prophylactic therapy, repetitive injections of the monoclonal antibody would require
well-functioning healthcare systems. Third, since monoclonal antibodies hardly cross the BBB, their
effectiveness to treat neurological complications would be certainly quite limited. Finally, an ideal drug
profile should also meet a reasonable cost/efficiency ratio, which might be challenging to achieve with
monoclonal antibody-based therapies, as for instance experienced with the high cost of the anti-RSV-F
palivizumab antibody [167,168].
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11.3. Anti-F Small-Molecule Blockers
Recently, Plemper and colleagues successfully developed a unique class of MeV fusion protein
small-molecule blocker (AS-48) [169]. The compounds were rationally designed based on a modelled
structure generated from the atomic coordinates of NDV F postfusion state (no prefusion state of
any paramyxovirus F proteins was available at this time). Importantly, although the F protein used
as a template was derived from the Edmonston vaccine strain, it was subsequently demonstrated
that the AS class of antiviral drugs exhibited broad-spectrum efficacy; not only the compounds could
block membrane fusion induced by multiple MeV strains (including wild-type isolates), but cell entry
and spread mediated by various CDV strains were similarly impaired, thus highlighting the potent
pan-morbillivirus inhibitory ability of this class of entry inhibitors [170–172].
Because a wide pocket located within the stalk domain of the postfusion F structure was originally
employed as a guide for drug design, it was assumed that the antiviral compound could bind to a
target site in a transiently emerging late F structural intermediate, in turn interfering with the transition
to the final postfusion state. Surprisingly, additional data were rather consistent with the AS-48 class
of morbillivirus fusion inhibitors exerting a stabilizing activity on prefusion F trimers (see below).
In any case, it is important to note that, despite (i) putative interaction with the prefusion F state
(substantially increasing the window of opportunity for compound interference); (ii) excellent efficacy
profiles even against CDV-mediated non-cytolytic spread in highly sensitive primary canine astrocytic
cultures [172]; and (iii) pan-morbillivirus efficacy [170–172], only intermediate antiviral potency could
be achieved in cultured cells (with low µM range efficacy) [172,173], which compromised further
profiling of the AS-48 small-molecule compound and derivative analogs in animal models.
11.4. Mechanism of Viral Resistance to AS-48 and Chemical Analogs
A complete understanding of resistance mechanisms must be acquired for clear decision-making
before the use of any novel antiviral candidates. As a matter of fact, the high inherent mutational rate
of RNA virus polymerases [174,175] favors the swift emergence of drug-resistant viral variants.
Regarding the AS-48 fusion inhibitor class, drug-resistant viral variants were efficiently generated
in cultured cells. Viral resistance to AS-48 can be achieved, at least in part, through mutations at MeV
F positions 462 and 367 [176]. In a postfusion F structural homology model, residue N462 (mapping
to the C-terminal region of HRB) contributes to the overall assembly of the 6HB structure, whereas
residue A367 (mapping within the DI domain) is located at the tip of the head domain, roughly 100 Å
away from residue N462. In sharp contrast, in a prefusion F model, both residues are in close proximity
(alpha carbons with less than 13Å distance) and localize at the structural transition of the short stalk
and the large globular head domains [177].
Concerning the mode of action of the fusion inhibitor, initial findings supported the hypothesis
that AS-48 docks into a pocket microdomain that transiently emerges in a late F structural intermediate,
thus preventing membrane fusion by interfering with proper transition to the postfusion conformation.
Drug design based on a postfusion F model and escape mutations mapping to the HRB region known
to contribute to 6HB formation favored a primary site resistance mechanism, which would compromise
high affinity interaction of the compound with the target site. However, although substitutions in HRB
emerged, neither naturally-occurring mutations in the opposite HRA binding partner were identified,
nor rationale substitutions at these HRA positions did result in drug-resistant F-mutants, which rather
supported the hypothesis of a secondary resistance mechanism [176,177].
Further complicating the interpretation of the data, resistance to AS-48 also correlated
with the emergence of mutations leading to F complexes characterized by a destabilizing
phenotype [176]. Interestingly, while mildly destabilized F-variants turned hyperfusogenic, the most
severely destabilized F complexes exhibited both improper cell surface transport competence and
fusion-deficiency. Remarkably, for those latter mutants, cell surface expression and ensuing bioactivity
could be reversed in the presence of the drug [176]. This prompted Prussia and colleagues to propose
a mechanism of viral resistance relying on accelerated F-refolding kinetics, which would translate in
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narrowing the window of opportunity for compound interference with a transiently emerging target
site [177].
Strikingly, a similar mechanism of resistance was recently proposed for RSV to efficiently escape
a panel of structurally diverse small-molecule fusion protein inhibitors, thus potentially spotlighting
a pan-paramyxovirus resistance mechanism [178]. On the other hand, Battles et al., very recently
determined the structure of RSV prefusion F in presence or absence of various antiviral drugs
(JNJ-2408068, JNJ-49153390, TMC-353121, BTA-9881, and BMS-433771 [179–181]). Remarkably, despite
displaying structurally diverse scaffolds, all compounds docked into a three-fold-axis central pocket
locating within the internal side of the prefusion F structure. They provided structural evidence
that the inhibitors-escape mutations either mapped to amino acids directly interacting with the
compounds or to the immediate neighboring ones that require conformational change to enable the
compounds to dock into the pocket [182]. Importantly, although drugs-escape mutations occurred in
similar F microdomains in both works, most of the reconstituted F-mutants in the latter study did not
exhibit hyperfusogenic phenotypes [182]. These data thus underscored three possible mechanisms
of resistance: two directly involved in preventing compounds high-affinity interaction (primary site
resistance model) and one relying on the overall destabilization of the metastable F conformation
(kinetics resistance model).
However, although possible for MeV F, the kinetics resistance model hardly explains why
the compound could nevertheless potently restore surface expression and bioactivity of inherently
destabilized F-mutants [176]. In fact, these findings additionally strongly supported the hypothesis
that the compound could still bind efficiently to F, which consequently also argued against a
primary site resistance mechanism. Three key additional molecular insights on the mode of action
exerted by AS-48 and the 3g chemical analog were recently provided. First, using newly identified
conformation-sensitive monoclonal antibodies, Ader and colleagues clearly demonstrated that 3g
efficiently stabilized the prefusion state of inherently destabilized F-mutants [137]. Second, refolding of
wild-type F trimers occurred at a substantially higher temperature in the presence than in the absence
of the drug [137]. Third, 3g prevented fusion induction presumably without blocking F-refolding
per se, since H/F-mediated fusion inhibition by 3g could be overcome by elevating the amount of
environmental energy [137].
Taken together, several lines of evidence support the notion that AS-48 and chemical analogs
preferentially bind to the prefusion-like F conformation rather than to a target site transiently emerging
in late structural intermediates [137,176]. In turn, the antiviral drug will exert a strong stabilizing
impact on metastable complexes, which translates in preventing productive H-mediated F-triggering
activity. Viruses with over-stabilized prefusion F trimers tend to accumulate mutations in specific
F microdomains resulting in increasing the inherent energy of the metastable state up to levels
re-accommodating H-mediated F-triggering. We speculate that the putatively faster refolding kinetics
and ensuing hyperfusogenicity associated with some F mutants in the absence of the drug may
represent the consequence rather than the cause of the resistance mechanism. In fact, we hypothesize
that the ensuing cascade of conformational changes (triggered if metastable F trimers display the
appropriate inherent energy) may be sterically and/or thermodynamically impaired by the compounds
occupying its target site, thereby potentially counteracting the putative mutations-driven faster
refolding kinetics.
Remarkably, the prefusion state-destabilization resistance model infers that some escape
F-mutants may even turn to be dependent on the antiviral compound to induce membrane fusion.
In fact, this is exactly the phenotype observed with the most severely destabilized F-variants: while
in the presence of the drug bioactivity was restored, in the absence, the prefusion state of such F
trimers was so labile that they spontaneously refolded into the postfusion state, thereby expressing
only bioactive-dead trimeric complexes at the cell surface [137,176].
Overall, regardless of the precise viral resistance mechanism against AS-48 class of entry inhibitors,
a large body of mechanistic and structural evidences illuminates “F trimer-destabilization” as one
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possible common theme used by paramyxovirus fusion proteins to escape structurally diverse viral
entry blockers [137,176,178]. Although any residues mapping along the broad protomer-protomer
interfaces may potentially destabilize trimeric F proteins, recent data strongly suggested the presence
of specific microdomains critical for proper stability of the prefusion state [137,148,176]. Corroborating
these data, a recent report by Poor and colleagues revealed, by oxidative footprinting assays, the
presence of critical microdomains involved in stabilizing the prefusion state of PIV5 F and ensuing
putative conformational changes required to achieve the postfusion conformation [183]. The existence
of hot spot prefusion conformation-stabilizing microdomains, which can accommodate mutations to
deliver pan-antiviral resistance, is strongly questioning the efficacy of targeting paramyxoviral fusion
proteins for the development of novel therapeutic options.
Although further research is necessary to identify definitive therapeutic drugs for use in MeV
infections, there are several promising targets and approaches. Importantly, pathogenicity of escape
viral variants must be carefully investigated in animal models to ensure that the emerging mutations
do not translate in enhanced virulence profiles, in particular with viruses developing hyperfusogenic
F proteins. In fact, although human clinical investigations were not performed, RSV variants which
developed pan-resistance to antiviral drug treatment remained fully pathogenic in a mouse model [178];
a phenotype that may nevertheless be strain-specific [182].
12. Functional Impact of the F Protein in Brain Disorders: A Highly Regulated or Dysregulated
Membrane Fusion Process?
Morbilliviruses are well known to be neurovirulent pathogens [34,35]. More than 50% of patients
with measles display abnormal electroencephalograms [184,185]. However the appearance of clinical
neurological disease remains rare in MeV infection. Nevertheless, as a result of viral persistence in the
brain, MeV can induce neurological diseases, such as SSPE or MIBE. While the former can occur years
after the acute phase of the disease in an otherwise normal patient, the latter may develop several
months following initial exposure in immunocompromised patients [186,187].
A panel of studies revealed that brain-isolated SSPE viruses (SSPE strains) accumulated extensive
mutations, which are thought to be potentially associated with neuro-virulence. Of particular
importance, mutations and/or deletions affecting the structural M, F and H proteins (well-known
components controlling viral assembly and budding) are often detected in SSPE strains [188–192].
Consequently, such viral variants are defective in producing infectious progeny and it is generally
assumed that ribonucleocapsids are transmitted from an infected cell to a naïve neighboring cell by
way of microfusion pores [55–57] (also referred to as intercellular membrane pores [58]).
While alterations in the cytoplasmic tail of F are considered a critical factor leading to
budding-deficient viruses and ensuing neurological disorders, recent reports identified several
substitutions in the F-ectodomain, which potentially may also confer neurovirulence. Indeed,
recombinant wild-type MeV carrying the mutations F-T461I or F-S103I/N462S/N465S exhibited
neurovirulence in suckling hamsters [193,194]. Importantly, functional and biochemical analyses of
the F-variants revealed that the mutations destabilized the metastable, prefusion conformation, which
consequently conferred hyperfusogenic phenotypes in SLAM- and N4-expressing cells. Remarkably,
such F complexes even gained the ability to induce syncytia formation in cells lacking the two main
morbillivirus receptors [194]. Furthermore, by introducing the mutation L454W in MeV F (a mutation
identified in two HIV-infected individuals additionally diagnosed with MIBE) [195], Jürgens and
colleagues recently confirmed the intriguing notion that F-variants of brain-derived MeV strains are
associated with destabilized and hyperfusogenic phenotypes [196]. This is of crucial importance with
regard to the future development of (and/or investigation of available) F inhibitors to eventually treat
MeV CNS infections, since brain-derived MeV viruses with destabilized F-variants may exhibit the
pan-resistance mechanism described above.
In sharp contrast, efficient cell-to-cell spread of CDV in the CNS of dogs occurs with wild-type
fusion complexes. Indeed, no mutations specifically associated with CNS-isolated CDV strains
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are known. Additionally, inoculation experiments with recombinant wild-type CDV in primary
canine brain cell cultures demonstrated that the virus could efficiently spread from cell-to-cell in a
non-cytolytic manner without the requirement of any mutations in the entry machinery [52,53]. Rather,
the findings supported the hypothesis that the CDV entry complex remained functional [59]. However,
in the CNS, the CDV fusion machinery is likely activated in a very selective manner, perhaps as a
consequence of (i) suboptimal interaction of H with a putative receptor expressed in astrocytes (GliaR)
and/or (ii) the recent discovery that wild-type prefusion F complexes are very stable [148]. Hence, for
CDV, microfusion pore formation would be the result of highly stable prefusion F complexes being
poorly activated by the low stimulus generated by H/GliaR contacts. Conversely, perhaps as a result
of the lack of candidate receptors for MeV in neurons, efficient lateral cell-to-cell spread may rely on
the accumulation of mutations in F trimers, causing the destabilization of the prefusion conformation
down to levels that bypass the direct requirement of signals promoted by the H/receptor interactions.
Taken together, although persistence in the brain seems to be a mechanism common to both MeV
and CDV to trigger neurological diseases, recent studies with MeV argue for the requirement of a
dysregulated fusion machinery to support the establishment of persistent CNS infections. In contrast,
recent data obtained with CDV argue for the hypothesis that highly regulated fusion machineries
are necessary to enable non-cytolytic cell-to-cell spread. It is thus tempting to speculate that these
contrasting findings may, at least in part, contribute to the well-known large difference in frequency of
neurological complications triggered by MeV and CDV infections in their respective hosts.
13. Conclusions and Perspectives
Research in recent years leaves no doubt that membrane fusion induced by morbilliviruses is
not only the first critical step of the infection but also determines cell pathology in specific tissues
and hence the course and outcome of the disease. The molecular and functional understanding of
morbillivirus-associated membrane fusion has progressed to the point where it has become feasible
to control this process by treating the fusion protein with inhibitory molecules. The variety of
approaches aiming to develop anti-F drugs combined with the gained knowledge on derived drug
resistance mechanisms [137,148,176,177], however, strongly suggest that combined therapies will
be a prerequisite for the development of entry inhibitors. Therefore, discovery of additional anti-F
small-molecule compounds with different inhibitory mechanisms and/or identification of anti-H
inhibitors may translate into a realistic therapeutic option in the near future. The primary aim will be
post-exposure treatment to contain local outbreaks by complementing WHO vaccination campaigns
that aim to eradicate measles [3]. A further potential application is the treatment of severe, particularly
neurological, MeV infections, which, albeit rare, are invariably crippling and lethal diseases.
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